Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model

Menopause

Volumn 14, Issue 4, 2007, Pages 639-647

  Wood, Charles E ^a   Sitruk Ware, Regine L ^b   Tsong, Yun Yen ^b   Register, Thomas C ^a   Lees, Cynthia J ^a   Cline, J Mark ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Macaca; Progesterone

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTRONE; KI 67 ANTIGEN; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN MCM5; SILASTIC; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER RISK; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; FEMALE GENITAL SYSTEM; GENE EXPRESSION; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; MENOPAUSAL SYNDROME; MENSTRUATION; MONKEY; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; VAGINA; VAGINA CYTOLOGY; WEIGHT REDUCTION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ANIMALS; BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CROSS-OVER STUDIES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; MACACA FASCICULARIS; OVARIECTOMY; POSTMENOPAUSE; PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34447344849     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000247017.41007.80     Document Type: Article

References (46)

1. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116.
2. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001;54:435-440.
3. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553.
4. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
7. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA 2000;284:691-694.
8. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
9. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909S-917S.
10. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3S-63S.
11. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11:356-367.
12. Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999;72:389-397.
13. de Lignieres B. Oral micronized progesterone. Clin Ther 1999;21:41-60.
14. de Lignieres B. Effects of progestogens on the postmenopausal breast. Climacteric 2002;5:229-235.
15. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
16. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 2002;100:853-863.
17. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
18. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys [e-pub]. Breast Cancer Res Treat 2006.
19. de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas 1995;21:251-257.
20. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185-202.
21. Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Andersen RN. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 1988;159:1203-1209.
22. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000;60:936-943.
23. Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859-1863.
24. Cicinelli E, de Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002;187:556-560.
25. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-941.
26. Maruo T, Mishell DR, Ben-Chetrit A, Hochner-Celnikier D, Hamada AL, Nash HA. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril 2002;78:1010-1016.
27. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-490.
28. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403-406.
29. Ficicioglu C, Gurbuz B, Tasdemir S, Yalti S, Canova H. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004;18:240-243.
30. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004;190:S54-S59.
31. Massai R, Miranda P, Valdes P, et al. Pre-registration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999;60:9-14.
32. Hamada AL, Maruo T, Samoto T, et al. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecol Endocrinol 2003;17:247-254.
33. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997;90:396-401.
34. Pasquale SA, Foldesy RG, Levine JP, Bachmann GA, Blackwell RE. Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women. Fertil Steril 1997;68:810-815.
35. Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516-521.
36. Cicinelli E, Borraccino V, Petruzzi D, Mazzotta N, Cerundolo ML, Schonauer LM. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1996;65:860-862.
37. Mircioiu C, Perju A, Neagu A, Griu E, Calin G, Miron DS. Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. Eur J Drug Metab Pharmacokinet 1998;23:391-396.
38. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-229.
39. Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006;66:1241-1249.
40. Lobo RA, Cassidenti DL. Pharmacokinetics of oral 17 β-estradiol. J Reprod Med 1992;37:77-84.
41. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44:622-626.
42. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220.
43. Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002;9:422-429.
44. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-298.
45. Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause 2005;12:232-237.
46. Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response. Lancet 1999;354:1447-1448